Welcome to our dedicated page for Hypha Labs news (Ticker: FUNI), a resource for investors and traders seeking the latest updates and insights on Hypha Labs stock.
Hypha Labs, Inc. (OTCQB: FUNI) generates news centered on its functional mushroom technologies, AI-powered Mushroom Accelerator™ systems, and MicroPearls™ ingredients. Company press releases and sponsored commentaries focus on product development milestones, patent activity, analytical capabilities, and strategic collaborations that shape its role in the functional mushroom and nutraceutical space.
Recent announcements highlight the filing of multiple patents covering mycelium cultivation systems, commercial accelerator configurations, and a replaceable sterile cartridge system, as well as a separate patent application for AI techniques used in the Mushroom Accelerator. Hypha Labs also reports on the integration of Artificial Intelligence, cloud connectivity, and mobile app control into its devices, along with over-the-air software updates.
News coverage includes R&D advances such as the acquisition of a High-Performance Liquid Chromatography (HPLC) machine and autosampler upgrade to refine potency measurements of MicroPearls compounds. The company has announced partnerships with organizations like Tryptomics for on-site analytical testing, metabolomics, and genetics support, and with Automated Technical Services to design a commercial-scale Mushroom Accelerator for nutraceutical ingredient production.
Hypha Labs also issues shareholder updates and commentary on regulatory developments around functional mushrooms and psilocybin, presenting these as part of the broader context for its technology. Investors and observers following FUNI news can expect updates on device capabilities, ingredient range, patent filings, analytical infrastructure, collaborations, and capital-raising efforts such as its disclosed Regulation A+ offering.
Hypha Labs (OTCQB:FUNI) announced a partnership with Mycology Resources to combine Hypha's Mushroom Accelerator and MicroPearls™ delivery system with Mycology Resources' cultivation, ingredient development, and global distribution.
The collaboration aims to commercialize scalable mushroom-based ingredients, create a vertically integrated production-to-distribution platform, and pursue participation in a functional mushroom market projected to exceed $76 billion by 2033.
Hypha Labs (OTCQB:FUNI) has launched Phase II of its strategic partnership with Tryptomics, combining Hypha's patented Mushroom Accelerator™ platform with Tryptomics' quality control and genomics services. The collaboration aims to develop proprietary bioreactor-optimized mushroom species and enhance quality assurance testing.
Key developments include the implementation of Tryptomics On-Site™ for in-house testing, third-party validation services, duplicate bioreactor deployment, and advanced genetics analysis through TryptoMatics™ and TryptoTyping™ technologies. The partnership enables rapid production of bioavailable Micro-Pearls in just 8 days, with the first new strains scheduled for launch in 2026.
Hypha Labs (OTCQB:FUNI) has partnered with Automated Technical Services (ATS) to scale up its Mushroom Accelerator technology for commercial production. The technology reduces mushroom compound production time from months to just eight days.
The collaboration aims to transform Hypha's countertop unit into an industrial-scale system for producing proprietary mushroom-based ingredients for the $33 billion global functional mushroom market, which is projected to reach $49 billion by 2028. ATS will work with Hypha's R&D team to adapt their laboratory processes for commercial production, targeting nutraceutical manufacturers worldwide.
The company is currently conducting a Regulation A+ public offering to support its expansion from consumer devices to large-scale ingredient production.
Hypha Labs (OTCQB:FUNI) has announced significant advancements in its Mushroom Accelerator technology, expanding its capability to produce various functional mushrooms in an eight-day home cultivation cycle. The enhanced device now supports the production of three popular mushroom varieties: Reishi, Lion's Mane, and Cordyceps.
The company's MicroPearls™ technology enables users to cultivate these mushrooms with their associated beneficial compounds, including triterpenes, polysaccharides, hericenones, erinacines, cordycepin, and adenosine. CEO Stone Douglass emphasizes that this innovation represents a significant improvement over traditional dried mushroom products, offering superior freshness and potency through on-demand production.
Hypha Labs (OTCQB:FUNI), an AI-powered functional mushroom company, provided a shareholder update highlighting significant developments. The company is finalizing its patent-pending Mushroom Accelerator technology, which enables mushroom cultivation in approximately eight days on a kitchen counter.
The update emphasizes the expanding market opportunity amid favorable regulatory changes for psilocybin. Notable developments include New Mexico becoming the third state to legalize medical psilocybin, joining Oregon and Colorado. The functional mushroom market is projected to grow from $33 billion in 2025 to $62 billion by 2032. CEO Stone Douglass expressed optimism about the company's position to capitalize on potential regulatory changes in the psychedelic therapeutics sector.
Hypha Labs (OTCQB:FUNI), a functional mushroom sciences company, has filed three new patents with the USPTO to protect its mushroom cultivation innovations. The patents include: 1) A Mushroom Accelerator System for mycelium cultivation using AI and cloud-based monitoring, 2) A Commercial Mushroom Accelerator System for large-scale production with modular cartridges, and 3) A Replaceable Sterile Cartridge System featuring AI-optimized growth processes. The company aims to implement a razor/razor blade business model through its cartridge system, targeting both home users and commercial kitchens.
The company has also enhanced its research capabilities with a new HPLC machine and variable loop autosampler upgrade to advance mushroom cultivation equipment and genetic research.Hypha Labs (OTCQB:FUNI), a functional mushroom sciences company, has announced two significant technological acquisitions: a new High-Performance Liquid Chromatography (HPLC) analytic machine and early access to Lucidity Systems' variable loop autosampler upgrade. The new equipment will enhance the company's ability to conduct precise measurements and analysis of MicroPearls™ products.
The technological upgrades will enable Hypha Labs to achieve higher potency resolution, more effective peak separation, and unprecedented accuracy in measuring Micropearl active compounds. This advancement is expected to improve research capabilities with their Mushroom Accelerator machine and lead to more consistent product outcomes.
Hypha Labs (OTCQB:FUNI) announces the signing of the 'Medical Psilocybin Act' (SB 219) by New Mexico Governor Michelle Lujan, establishing the third state-legal psilocybin access system in the United States. The legislation will allow patients with qualifying conditions to access psilocybin under licensed healthcare provider supervision.
The company, known for its MicroPearls™ product line, is developing a device for home-based mushroom ingredient production with 8-day growth cycles. CEO Stone Douglass describes this legislative development as a 'watershed event' for functional mushrooms, anticipating that other jurisdictions will follow New Mexico's example.